Items Tagged ‘Multiple Myeloma’

March 28, 2018

AbbVie and the International Myeloma Foundation Partner to Study Role of a Genetic Mutation in Multiple Myeloma

By

AbbVie a research and development-based global biopharmaceutical company, and the International Myeloma Foundation (IMF) today announced they have entered into a collaboration to conduct a landmark retrospective chart review study to better understand and help manage multiple myeloma (MM), the second most common blood cancer.1 “There are significant knowledge gaps about multiple myeloma, and among […]

View full entry

Tags: abbvie, Multiple Myeloma, myeloma treatment, News, Precision Cancer Medicine


March 14, 2018

CRISPR Enhances Cancer Immunotherapy

By

Gene editing expands reach of therapeutic T cells, in mice CancerConnect News: Last year, the Food and Drug Administration approved the first cellular immunotherapies to treat cancer. These therapies involve collecting a patient’s own immune cells — called T cells — and supercharging them to home in on and attack specific blood cancers, such as […]

View full entry

Tags: CAR T Cells, CRSIPR, immunotherapy, Leukemia, Multiple Myeloma, News


March 7, 2018

Darzalex-Effective Treatment for Smoldering Multiple Myeloma

By

CancerConnect News: The use of Darzalex (daratumumab) in smoldering myeloma may be effective in delaying the time to disease progression. These results were presented at the 2017 annual meeting of the American Society of Hematology (ASH). Multiple myeloma (MM) is the second most common blood cancer in the United States, with over 30,000 diagnoses expected […]

View full entry

Tags: Multiple Myeloma, News


February 8, 2018

Kyprolis Improves Survival in Recurrent Multiple Myeloma

By

CancerConnect News: The addition of Kyprolis® (carfilzomib) to the standard treatment regimen, Revlimid® (lenalidomide) and dexamethasone, improves survival for patients with multiple myeloma whose disease progressed or recurred following prior therapies. These results were recently presented at the 2017 annual meeting of the American Society of Hematology (ASH). About Multiple Myeloma In the United States […]

View full entry

Tags: kyprolis, Multiple Myeloma, News, revlimid


February 7, 2018

Diagnosed with Multiple Myeloma: 10 Tips on How to Get The Most From Your Doctor

By

1) Choose Your Doctor Carefully Hematologists and oncologists are the primary doctors involved with multiple myeloma and often work in collaboration with stem cell transplant physicians. Pick your primary hematologist/oncologist carefully, rely on people you trust including nurses and other health care professionals who make help with recommendations.  Make sure your doctor is someone you […]

View full entry

Tags: Multiple Myeloma, News


January 17, 2018

Xgeva Approved for The Treatment of Multiple Myeloma

By

CancerConnect News: The US Food and Drug Administration (FDA) has expanded the approval of Xgeva (denosumab) for the prevention of skeletal-related events in patients with bone metastasis from multiple myeloma. In multiple myeloma, plasma cells infiltrate the bone marrow, spreading into the cavities of all the large bones of the body. In a majority of […]

View full entry

Tags: Bone Metastases, Multiple Myeloma, News, treatment, Xgeva, Zometa


December 13, 2017

Addition of Darzalex™ Improves Outcomes in Newly Diagnosed Multiple Myeloma

By

The addition of Darzalex (daratumumab) to the standard treatment combination consisting of Velcade (bortezomib), melphalan, and prednisone (VMP) reduces disease progression or death by 50%, among patients with newly diagnosed multiple myeloma who are not eligible to undergo a stem cell transplant. These results were presented as a late-breaking abstract at the 2017 annual meeting […]

View full entry

Tags: bortezomib, daratumumab, Darzalex, melphalan, Multiple Myeloma, News, Precision Cancer Medicine, prednisone, velcade, VMP


November 20, 2017

Diagnosed with Multiple Myeloma: 10 Tips on How to Get The Most From Your Doctor

By

1) Choose Your Doctor Carefully Hematologists and oncologists are the primary doctors involved with multiple myeloma and often work in collaboration with stem cell transplant physicians. Pick your primary hematologist/oncologist carefully, rely on people you trust including nurses and other health care professionals who make help with recommendations.  Make sure your doctor is someone you […]

View full entry

Tags: Multiple Myeloma, News


September 25, 2017

FDA Adds Two Roche Multiple Myeloma Studies Evaluating Checkpoint Inhibitors to List of Partial Clinical Holds Over Safety Concerns

By

Alarmed that an imbalance in deaths among patients taking a combination of Keytruda (pembrolizumab) with Celgene’s Pomalyst and Revlimid could represent a threat in that whole class of checkpoint comboinations, the FDA has added two Tecentriq (atezolizumab) clinical studies to its growing list of clinical trials placed on partial hold over safety concerns while further […]

View full entry

Tags: checkpoint inhibitors, immunotherapy, Multiple Myeloma, News, PD-1, PD-L1


August 16, 2017

Bone Marrow Transplant Program Celebrates Its First Year

By msequeira msequeira

The Bone Marrow Transplant Program at the UNM Comprehensive Cancer Center has been treating people with blood disorders for a little more than a year. The first people to be treated are now celebrating one year since their treatment ended. New Mexicans no longer need to leave home to get access to these kinds of […]

View full entry

Tags: blood cancer, Blood transfusions, Lymphoma, Multiple Myeloma


April 22, 2015

Panobinostat

By

Class: Biological Therapy Generic Name: Panobinostat Trade Name: Farydak® For which conditions is this drug approved? Farydak® is approved for use, in combination with Velcade® (bortezomib) and dexamethasone, in people with multiple myeloma after they’ve had at least two other types of treatment. What is the mechanism of action? Farydak is an agent known as a […]

View full entry

Tags: Biological Therapy, Drug Dictionary, farydak, Multiple Myeloma, P, panobinostat


April 22, 2015

Farydak®

By

Class: Biological Therapy Generic Name: Panobinostat Trade Name: Farydak® For which conditions is this drug approved? Farydak® is approved for use, in combination with Velcade® (bortezomib) and dexamethasone, in people with multiple myeloma after they’ve had at least two other types of treatment. What is the mechanism of action? Farydak is an agent known as a […]

View full entry

Tags: Biological Therapy, Drug Dictionary, F, farydak, Multiple Myeloma, panobinostat


March 18, 2009

Multiple Myeloma Overview

By

Overview Multiple myeloma is a cancer of plasma cells. Plasma cells are a special type of white blood cell that are part of the body’s immune system. Plasma cells normally live in the bone marrow and make proteins, called antibodies, that circulate in the blood and help fight certain types of infections. Plasma cells also […]

View full entry

Tags: Multiple Myeloma


February 6, 2009

Understanding Stem Cell Transplants

By

High-dose chemotherapy and bone marrow or blood stem cell transplantation (SCT) remains the best treatment available for selected patients with certain types of leukemia. The SCT process was developed more than 36 years ago and was considered such a major development of biomedical science that the individuals responsible were awarded the Nobel Prize for Medicine […]

View full entry

Tags: Hodgkin's Lymphoma, Multiple Myeloma